Skip to main content
SpringerLink
Log in

NICE recommends apixiban and ranibizumab . . .

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. incremental cost-effectiveness ratio

References

  1. NICE. NICE recommends new treatment option for people with common heart condition - 27 February 2013. Media Release : 27 Feb 2013. Available from: URL: http://www.nice.org.uk

  2. NICE. NICE gives green light to ranibizumab for diabetic macular oedema in final guidance after rapid review. Media Release : 27 Feb 2013. Available from: URL: http://www.nice.org.uk

  3. NICE. NICE consults on pemetrexed for the maintenance treatment of non-small-celllung cancer. Media Release : 21 Feb 2013. Available from: URL: http://www.nice.org.uk

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

NICE recommends apixiban and ranibizumab . . .. PharmacoEcon Outcomes News 673, 11 (2013). https://doi.org/10.1007/s40274-013-0225-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-013-0225-9

Search

Navigation